GB201206628D0 - Subcutaneous administration of PEGylated blood clotting factors - Google Patents

Subcutaneous administration of PEGylated blood clotting factors

Info

Publication number
GB201206628D0
GB201206628D0 GBGB1206628.8A GB201206628A GB201206628D0 GB 201206628 D0 GB201206628 D0 GB 201206628D0 GB 201206628 A GB201206628 A GB 201206628A GB 201206628 D0 GB201206628 D0 GB 201206628D0
Authority
GB
United Kingdom
Prior art keywords
subcutaneous administration
blood clotting
clotting factors
pegylated blood
pegylated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB1206628.8A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
LEVERTON LICENCE HOLDINGS Ltd
Original Assignee
LEVERTON LICENCE HOLDINGS Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by LEVERTON LICENCE HOLDINGS Ltd filed Critical LEVERTON LICENCE HOLDINGS Ltd
Priority to GBGB1206628.8A priority Critical patent/GB201206628D0/en
Publication of GB201206628D0 publication Critical patent/GB201206628D0/en
Priority to US14/394,437 priority patent/US20150086524A1/en
Priority to GB1418864.3A priority patent/GB2516388A/en
Priority to PE2014001639A priority patent/PE20150226A1/en
Priority to PCT/EP2013/057928 priority patent/WO2013156488A2/en
Priority to MX2014012512A priority patent/MX2014012512A/en
Priority to AP2014008049A priority patent/AP2014008049A0/en
Priority to GBGB1910190.6A priority patent/GB201910190D0/en
Priority to GBGB1910184.9A priority patent/GB201910184D0/en
Priority to EP13719043.5A priority patent/EP2838566A2/en
Priority to KR1020147031042A priority patent/KR102137290B1/en
Priority to EA201491702A priority patent/EA033469B1/en
Priority to GEAP201313632A priority patent/GEP201706716B/en
Priority to IL235129A priority patent/IL235129B/en
Priority to JP2015504987A priority patent/JP2015512927A/en
Priority to AU2013248296A priority patent/AU2013248296A1/en
Priority to CA2869993A priority patent/CA2869993C/en
Priority to MD20140123A priority patent/MD20140123A2/en
Priority to CN201380027958.3A priority patent/CN104411335A/en
Priority to BR112014025737A priority patent/BR112014025737A2/en
Priority to MYPI2014002900A priority patent/MY190257A/en
Priority to IN8598DEN2014 priority patent/IN2014DN08598A/en
Priority to NZ701205A priority patent/NZ701205A/en
Priority to SG11201406492YA priority patent/SG11201406492YA/en
Priority to ZA2014/07370A priority patent/ZA201407370B/en
Priority to CR20140475A priority patent/CR20140475A/en
Priority to CL2014002773A priority patent/CL2014002773A1/en
Priority to NI201400122A priority patent/NI201400122A/en
Priority to PH12014502314A priority patent/PH12014502314A1/en
Priority to ECIEPI201423048A priority patent/ECSP14023048A/en
Priority to MX2020014208A priority patent/MX2020014208A/en
Priority to CO14252826A priority patent/CO7151496A2/en
Priority to HK15100881.5A priority patent/HK1200695A1/en
Priority to US15/691,090 priority patent/US11351112B2/en
Priority to JP2017171545A priority patent/JP6550107B2/en
Priority to AU2018200111A priority patent/AU2018200111B2/en
Priority to JP2019073048A priority patent/JP2019131593A/en
Priority to AU2020200842A priority patent/AU2020200842A1/en
Ceased legal-status Critical Current

Links

GBGB1206628.8A 2012-04-16 2012-04-16 Subcutaneous administration of PEGylated blood clotting factors Ceased GB201206628D0 (en)

Priority Applications (38)

Application Number Priority Date Filing Date Title
GBGB1206628.8A GB201206628D0 (en) 2012-04-16 2012-04-16 Subcutaneous administration of PEGylated blood clotting factors
GB1418864.3A GB2516388A (en) 2012-04-16 2013-04-16 Optimised subcutaneous therapeutic agents
CN201380027958.3A CN104411335A (en) 2012-04-16 2013-04-16 Optimised subcutaneous therapeutic agents
MYPI2014002900A MY190257A (en) 2012-04-16 2013-04-16 Optimised subcutaneous therapeutic agents
PE2014001639A PE20150226A1 (en) 2012-04-16 2013-04-16 OPTIMIZED THERAPEUTIC AGENTS FOR SUBCUTANEOUS ADMINISTRATION
PCT/EP2013/057928 WO2013156488A2 (en) 2012-04-16 2013-04-16 Optimised subcutaneous therapeutic agents
MX2014012512A MX2014012512A (en) 2012-04-16 2013-04-16 Optimised subcutaneous therapeutic agents.
AP2014008049A AP2014008049A0 (en) 2012-04-16 2013-04-16 Optimised subcuraneous therapeutic agents
GBGB1910190.6A GB201910190D0 (en) 2012-04-16 2013-04-16 Optimised subsutaneous therapeutic agents
GBGB1910184.9A GB201910184D0 (en) 2012-04-16 2013-04-16 Optimised subcutaneous therapeutic agents
BR112014025737A BR112014025737A2 (en) 2012-04-16 2013-04-16 method for administering a therapeutic agent, method for preventing entry of a therapeutic agent, method for modulating the rate of release of a therapeutic agent, therapeutic agent, dosage forms, method of treating a disease and parts kit
KR1020147031042A KR102137290B1 (en) 2012-04-16 2013-04-16 Optimised subcutaneous therapeutic agents
EA201491702A EA033469B1 (en) 2012-04-16 2013-04-16 Subcutaneous administration of blood factor conjugates with polyethylene glycol
GEAP201313632A GEP201706716B (en) 2012-04-16 2013-04-16 Optimised subcutaneous therapeutic agents
IL235129A IL235129B (en) 2012-04-16 2013-04-16 Optimised subcutaneous therapeutic agents
JP2015504987A JP2015512927A (en) 2012-04-16 2013-04-16 Optimized subcutaneous therapy
AU2013248296A AU2013248296A1 (en) 2012-04-16 2013-04-16 Optimised subcutaneous therapeutic agents
CA2869993A CA2869993C (en) 2012-04-16 2013-04-16 Optimised subcutaneous therapeutic agents
MD20140123A MD20140123A2 (en) 2012-04-16 2013-04-16 Optimised subcutaneous therapeutic agents
US14/394,437 US20150086524A1 (en) 2012-04-16 2013-04-16 Optimised subcutaneous therapeutic agents
EP13719043.5A EP2838566A2 (en) 2012-04-16 2013-04-16 Optimised subcutaneous therapeutic agents
IN8598DEN2014 IN2014DN08598A (en) 2012-04-16 2013-04-16
SG11201406492YA SG11201406492YA (en) 2012-04-16 2013-04-16 Optimised subcutaneous therapeutic agents
NZ701205A NZ701205A (en) 2012-04-16 2013-04-16 Optimised subcutaneous therapeutic agents
ZA2014/07370A ZA201407370B (en) 2012-04-16 2014-10-10 Optimised subcutaneous therapeutic agents
CR20140475A CR20140475A (en) 2012-04-16 2014-10-14 OPTIMIZED SUBCUTANEOUS ADMINISTRATION THERAPEUTIC AGENTS
NI201400122A NI201400122A (en) 2012-04-16 2014-10-15 THERAPEUTIC AGENTS FOR OPTIMIZED SUBCUTANEOUS ADMINISTRATION
CL2014002773A CL2014002773A1 (en) 2012-04-16 2014-10-15 A subcutaneous dosage form of a pharmaceutical composition of a blood coagulation factor selected from factor vii, viia, viii, ix, x, xa, xi, xiii, v, von willebrand factor and protein c, conjugated with a polyethylene glycol molecule (peg), where the dosage of the factor is 100 and 250 iu / kg or 25 and 50 iu / kg, and where the peg molecule is conjugated directly or indirectly.
PH12014502314A PH12014502314A1 (en) 2012-04-16 2014-10-15 Optimised subcutaneous therapeutic agents
ECIEPI201423048A ECSP14023048A (en) 2012-04-16 2014-10-16 OPTIMIZED THERAPEUTIC AGENTS FOR SUBCUTANEOUS ADMINISTRATION
MX2020014208A MX2020014208A (en) 2012-04-16 2014-10-16 Optimised subcutaneous therapeutic agents.
CO14252826A CO7151496A2 (en) 2012-04-16 2014-11-14 Therapeutic agents for optimized subcutaneous administration
HK15100881.5A HK1200695A1 (en) 2012-04-16 2015-01-27 Optimised subcutaneous therapeutic agents
US15/691,090 US11351112B2 (en) 2012-04-16 2017-08-30 Optimised subcutaneous therapeutic agents
JP2017171545A JP6550107B2 (en) 2012-04-16 2017-09-06 Optimized subcutaneous drug
AU2018200111A AU2018200111B2 (en) 2012-04-16 2018-01-05 Optimised subcutaneous therapeutic agents
JP2019073048A JP2019131593A (en) 2012-04-16 2019-04-05 Optimized subcutaneous therapeutic agents
AU2020200842A AU2020200842A1 (en) 2012-04-16 2020-02-06 Optimised subcutaneous therapeutic agents

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1206628.8A GB201206628D0 (en) 2012-04-16 2012-04-16 Subcutaneous administration of PEGylated blood clotting factors

Publications (1)

Publication Number Publication Date
GB201206628D0 true GB201206628D0 (en) 2012-05-30

Family

ID=46209105

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB1206628.8A Ceased GB201206628D0 (en) 2012-04-16 2012-04-16 Subcutaneous administration of PEGylated blood clotting factors

Country Status (1)

Country Link
GB (1) GB201206628D0 (en)

Similar Documents

Publication Publication Date Title
IL269877B (en) Blood pump systems and methods
HK1216397A1 (en) Medical infusion system allowing automatic priming
EP2869866A4 (en) Catheter pump
SG11201405470WA (en) Infusion pump
EP2902048A4 (en) Infusion pump
EP2902047A4 (en) Infusion pump
SG11201500928WA (en) Infusion pump
EP2914322A4 (en) Quiet nasal cannula
EP2813709A4 (en) Blood pump
PT2911716T (en) Device for extracorporeal blood treatment
EP2814553A4 (en) Anchoring an intravenous cannula
EP2814548A4 (en) Medical cannula package
EP2885028A4 (en) Disposable injector
PL3473191T3 (en) Living donor cannula
GB201207543D0 (en) Treatment of transfusion blood
SG11201500818TA (en) Arterial cannula which allows perfusion along opposing directions within a cannulated vessel
GB2502767B (en) Cannula
EP2906268A4 (en) Infusion system disposable alignment system
HK1200695A1 (en) Optimised subcutaneous therapeutic agents
GB2499286B (en) Two-part cannula dressing
EP2830642A4 (en) Subcutaneous administration of iduronate- 2-sulfatase
EP2849817A4 (en) Systems and methods for extracorporeal blood modification
HK1204056A1 (en) Blood glucose meter
EP2902051A4 (en) Syringe pump
GB2503963C (en) Patient garment

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)
S30Z Assignments for licence or security reasons

Free format text: APPLICANT. LEVERTON LICENCE HOLDINGS LIMITED SECURITY INTEREST. FONDS RUSNANO CAPITAL S.A.